194 related articles for article (PubMed ID: 14711480)
1. In vitro pharmacodynamic activity of gatifloxacin, gemifloxacin, moxifloxacin and levofloxacin against Streptococcus pneumoniae containing specific mutations in DNA gyrase and topoisomerase IV.
Garrison MW; Schimmels JA; Madaras-Kelly KJ
Diagn Microbiol Infect Dis; 2003 Dec; 47(4):587-93. PubMed ID: 14711480
[TBL] [Abstract][Full Text] [Related]
2. Fluoroquinolone resistance in Streptococcus pneumoniae: area under the concentration-time curve/MIC ratio and resistance development with gatifloxacin, gemifloxacin, levofloxacin, and moxifloxacin.
LaPlante KL; Rybak MJ; Tsuji B; Lodise TP; Kaatz GW
Antimicrob Agents Chemother; 2007 Apr; 51(4):1315-20. PubMed ID: 17296740
[TBL] [Abstract][Full Text] [Related]
3. Relative potential for selection of quinolone-resistance-determining-region mutations in Streptococcus pneumoniae by gemifloxacin, gatifloxacin and moxifloxacin.
De Azavedo JC; Duncan CL; Kilburn L; Downar J; Kong B; Lad S; Low DE; Bast DJ
J Chemother; 2006 Aug; 18(4):373-8. PubMed ID: 17024792
[TBL] [Abstract][Full Text] [Related]
4. In vitro pharmacodynamics of moxifloxacin versus levofloxacin against 4 strains of Streptococcus pneumoniae: 1 wild type, 2 first-step parC mutants, and 1 pump mutant.
Schafer J; Hovde LB; Simonson D; Rotschafer JC
Diagn Microbiol Infect Dis; 2008 Feb; 60(2):155-61. PubMed ID: 17910998
[TBL] [Abstract][Full Text] [Related]
5. In vivo activity of gemifloxacin, moxifloxacin and levofloxacin against pneumococci with gyrA and parC point mutations in a sepsis mouse model measured with the all or nothing mortality end-point.
Alkorta M; Giménez MJ; Vicente D; Aguilar L; Pérez-Trallero E
Int J Antimicrob Agents; 2005 Feb; 25(2):163-7. PubMed ID: 15664487
[TBL] [Abstract][Full Text] [Related]
6. Single- and multi-step resistance selection study of gemifloxacin compared with trovafloxacin, ciprofloxacin, gatifloxacin and moxifloxacin in Streptococcus pneumoniae.
Nagai K; Davies TA; Dewasse BE; Jacobs MR; Appelbaum PC
J Antimicrob Chemother; 2001 Sep; 48(3):365-74. PubMed ID: 11533001
[TBL] [Abstract][Full Text] [Related]
7. Correlation between in vitro and in vivo activity of levofloxacin and moxifloxacin against pneumococcal strains with different susceptibilities to fluoroquinolones.
Huelves L; Sevillano D; Martínez-Marín C; López-Casla MT; Gracia M; Alou L; del Carmen Ponte M; Prieto J; Soriano F;
Int J Antimicrob Agents; 2006 Apr; 27(4):294-9. PubMed ID: 16527462
[TBL] [Abstract][Full Text] [Related]
8. Pharmacodynamics of moxifloxacin and levofloxacin at simulated epithelial lining fluid drug concentrations against Streptococcus pneumoniae.
Florea NR; Tessier PR; Zhang C; Nightingale CH; Nicolau DP
Antimicrob Agents Chemother; 2004 Apr; 48(4):1215-21. PubMed ID: 15047522
[TBL] [Abstract][Full Text] [Related]
9. Cleavable-complex formation by wild-type and quinolone-resistant Streptococcus pneumoniae type II topoisomerases mediated by gemifloxacin and other fluoroquinolones.
Yague G; Morris JE; Pan XS; Gould KA; Fisher LM
Antimicrob Agents Chemother; 2002 Feb; 46(2):413-9. PubMed ID: 11796351
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of bacterial kill when modelling the bronchopulmonary pharmacokinetic profile of moxifloxacin and levofloxacin against parC-containing isolates of Streptococcus pneumoniae.
Deryke CA; Du X; Nicolau DP
J Antimicrob Chemother; 2006 Sep; 58(3):601-9. PubMed ID: 16857688
[TBL] [Abstract][Full Text] [Related]
11. Mutant prevention concentrations for single-step fluoroquinolone-resistant mutants of wild-type, efflux-positive, or ParC or GyrA mutation-containing Streptococcus pneumoniae isolates.
Smith HJ; Walters M; Hisanaga T; Zhanel GG; Hoban DJ
Antimicrob Agents Chemother; 2004 Oct; 48(10):3954-8. PubMed ID: 15388458
[TBL] [Abstract][Full Text] [Related]
12. Activities of mutant prevention concentration-targeted moxifloxacin and levofloxacin against Streptococcus pneumoniae in an in vitro pharmacodynamic model.
Allen GP; Kaatz GW; Rybak MJ
Antimicrob Agents Chemother; 2003 Aug; 47(8):2606-14. PubMed ID: 12878526
[TBL] [Abstract][Full Text] [Related]
13. The selection of resistance to and the mutagenicity of different fluoroquinolones in Staphylococcus aureus and Streptococcus pneumoniae.
Sierra JM; Cabeza JG; Ruiz Chaler M; Montero T; Hernandez J; Mensa J; Llagostera M; Vila J
Clin Microbiol Infect; 2005 Sep; 11(9):750-8. PubMed ID: 16104991
[TBL] [Abstract][Full Text] [Related]
14. Gatifloxacin, gemifloxacin, and moxifloxacin: the role of 3 newer fluoroquinolones.
Saravolatz LD; Leggett J
Clin Infect Dis; 2003 Nov; 37(9):1210-5. PubMed ID: 14557966
[TBL] [Abstract][Full Text] [Related]
15. Susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada.
Patel SN; McGeer A; Melano R; Tyrrell GJ; Green K; Pillai DR; Low DE;
Antimicrob Agents Chemother; 2011 Aug; 55(8):3703-8. PubMed ID: 21628545
[TBL] [Abstract][Full Text] [Related]
16. Single and multi-step resistance selection study in Streptococcus pneumoniae comparing ceftriaxone with levofloxacin, gatifloxacin and moxifloxacin.
Browne FA; Clark C; Bozdogan B; Dewasse BE; Jacobs MR; Appelbaum PC
Int J Antimicrob Agents; 2002 Aug; 20(2):93-9. PubMed ID: 12297357
[TBL] [Abstract][Full Text] [Related]
17. Mutations in the quinolone resistance determining region in Staphylococcus epidermidis recovered from conjunctiva and their association with susceptibility to various fluoroquinolones.
Yamada M; Yoshida J; Hatou S; Yoshida T; Minagawa Y
Br J Ophthalmol; 2008 Jun; 92(6):848-51. PubMed ID: 18460536
[TBL] [Abstract][Full Text] [Related]
18. Comparative study of the mutant prevention concentrations of moxifloxacin, levofloxacin, and gemifloxacin against pneumococci.
Credito K; Kosowska-Shick K; McGhee P; Pankuch GA; Appelbaum PC
Antimicrob Agents Chemother; 2010 Feb; 54(2):673-7. PubMed ID: 20008781
[TBL] [Abstract][Full Text] [Related]
19. In vitro activity of gemifloxacin against clinical isolates of Neisseria gonorrhoeae with and without mutations in the gyrA gene.
Ruiz J; Marco F; Sierra JM; Aguilar L; Garcia-Mendez E; Mensa J; Jiménez De Anta MT; Vila J
Int J Antimicrob Agents; 2003 Jul; 22(1):73-6. PubMed ID: 12842332
[TBL] [Abstract][Full Text] [Related]
20. Activities of clinafloxacin, gatifloxacin, gemifloxacin, and trovafloxacin against recent clinical isolates of levofloxacin-resistant Streptococcus pneumoniae.
Jorgensen JH; Weigel LM; Swenson JM; Whitney CG; Ferraro MJ; Tenover FC
Antimicrob Agents Chemother; 2000 Nov; 44(11):2962-8. PubMed ID: 11036007
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]